<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>A randomized, crossover study compared the effects of <z:chebi fb="0" ids="39548">atorvastatin</z:chebi>, <z:chebi fb="0" ids="5296">gemfibrozil</z:chebi> and their combination on inflammatory markers in type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="1" pm="."><plain>C-reactive protein (CRP), <z:chebi fb="1" ids="6495">lipoprotein</z:chebi>-associated phospholipase A2 (Lp-PLA2), secretory phospholipase A2 (sPLA2), interleukin 8 (IL8), monocyte chemotactic protein 1 (MCP1) and <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> <z:mp ids='MP_0001651'>necrosis</z:mp> factor α (TNFα) were measured </plain></SENT>
<SENT sid="2" pm="."><plain>Both <z:chebi fb="23" ids="18059">lipid</z:chebi>-lowering drugs had positive, complementary and additive effects on inflammatory markers, which were closely related to baseline inflammatory status </plain></SENT>
</text></document>